Aktiesnakken — Juni 2013
-
Roche har dog fordelen af at kende markedet ud og ind
-
Omvendt må Arzerra måske stå stærkest ifht. kombibehandlig med kinase inhibitorer i fremtiden ??? især da GA101 er giftig i forvejen
-
det er kun arzerra - GA101 er allerede kommet
-
nej, det er rigtgit - men med alle de sammenligninger, der allerede bliver foretaget - så bliver det godt at blive uddannet lidt mere
-
var det 22%
-
well, det er jo rent gætværk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind